Three insights:
1. Yutiq is an FDA-approved, three-year micro-insert for the treatment of chronic, non-infectious posterior segment uveitis.
2. Yutiq utilizes EyePoint’s Durasert drug delivery technology. It contains 0.18 milligrams of fluocinolone acetonide, designed to release consistently for up to 36 months.
3. In conjunction, the company launched EyePoint Assist, a program to ensure eligible patients in need of financial assistance have access to Yutiq.
More articles on improving performance:
How hospitals will handle outpatient competition & disruption in 2019 — 5 takeaways
5 must-read articles for the ASC industry this week: Jan. 25-Feb. 1
University Hospital renames outpatient facility — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
